Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BC 007 - Dragonboat Biopharmaceutical

Next Previous
X
Search
Drug Profile

BC 007 - Dragonboat Biopharmaceutical

Alternative Names: Anti-CLDN 18.2/CD47 bi-specific antibody - Dragonboat Biopharmaceutical; BC-007 - Dragonboat Biopharmaceutical; CLDN 18.2/CD47 bsAb - Dragonboat Biopharmaceutical

Latest Information Update: 28 Jun 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dragonboat Biopharmaceutical
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunomodulators; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 28 Jun 2022 Safety and pharmacodynamics data from preclinical studies in solid tumors released by Dragonboat Biopharmaceutical
  • 25 Jun 2022 Preclinical trials in Solid tumours in China (Parenteral) (Dragoncoat Biopharmaceutical pipeline, June 2022)
  • 25 Jun 2022 Dragonboat Biopharmaceutical files a clinical trial application (CTA) with the National Medical Products Administration (NMPA) in China for solid tumours (Late-stage disease) prior to June 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top